[
    [
        {
            "time": "2018-10-01",
            "original_text": "Top Biotech Stocks to Buy in October",
            "features": {
                "keywords": [
                    "Biotech",
                    "Stocks",
                    "Buy",
                    "October"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Top Biotech Stocks to Buy in October",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-02",
            "original_text": "SHAREHOLDER ALERT: SKX PM USAT MCHP ABBV ALNY MGTI CPB CHGG ADNT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines",
            "features": {
                "keywords": [
                    "SHAREHOLDER",
                    "ALERT",
                    "Class",
                    "Action",
                    "Deadlines"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "SHAREHOLDER ALERT: SKX PM USAT MCHP ABBV ALNY MGTI CPB CHGG ADNT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-03",
            "original_text": "AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Orilissa",
                    "Canadian",
                    "Nod",
                    "Endometriosis"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-04",
            "original_text": "AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Orilissa",
                    "Canadian",
                    "Nod",
                    "Endometriosis"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-05",
            "original_text": "AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Upadacitinib",
                    "HUMIRA",
                    "Annual",
                    "Meeting"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]